** Shares of telehealth firm Hims & Hers HIMS.N rise 11.4% to $35.29

** A panel of advisers to the U.S. Food and Drug Administration on Thursday voted to place a widely used peptide called BPC-157 on a list that would allow broader pharmacy compounding

** Hims is set to tap what analysts estimate could be ​a multi-billion-dollar market for peptides if U.S. regulators loosen manufacturing restrictions

** Chief Medical Officer Anant Vinjamoori tells panel Hims stands to benefit commercially if BPC-157 were added to the 503A list

** We think longer still before it could become a meaningful contributor to HIMS, as the company has expressed that it does not necessarily want to rush to be first to market, says brokerage Leerink

** Brokerage adds (the latest) outcome is a positive catalyst for the stock as BPC-157 is likely one of the more commercially viable of the seven peptides for a broad audience.

** HIMS up 6% YTD